A Patient With Metastatic Breast Cancer 15 Years After Bilateral Prophylactic Total Mastectomy and Oophorectomy

Abstract

Introduction It is estimated that 5%–10% of breast cancer is hereditary with 60%–70% of those arising from a Breast Cancer gene mutation in clinical practice (BRCA)1 or BRCA2 mutation. Women with RCA1 or BRCA2 mutations have a 55%–85% lifetime risk of nvasive breast cancer. Among women with BRCA1, 36%–63% deelop ovarian cancer and among patients with BRCA2 10%–27% evelop ovarian cancer. BRCA1-related breast cancers tend to be of he basal subtype, with predominant lymphocytic infiltration, and re often more aggressive and associated with negative prognostic actors. They are usually Estrogen (ER)/Progesterone (PR)/ ER2neu negative. BRCA2-related breast cancers tend to be of the uminal type, and are usually ER/PR positive. The median age of reast cancer onset ranges from 40 to 50 years in BRCA1 and RCA2 carriers compared with 60–70 years in sporadic cases.